These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24072197)

  • 1. The effect of tuberculosis treatment on virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic review.
    Soeters HM; Napravnik S; Patel MR; Eron JJ; Van Rie A
    AIDS; 2014 Jan; 28(2):245-55. PubMed ID: 24072197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children.
    Soeters HM; Sawry S; Moultrie H; Rie AV
    J Acquir Immune Defic Syndr; 2014 Oct; 67(2):136-44. PubMed ID: 25072611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
    Shoko C; Chikobvu D; Bessong PO
    S Afr Med J; 2020 Mar; 110(4):313-319. PubMed ID: 32657744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tuberculosis on the kinetics of CD4(+) T cell count among HIV-infected patients who initiated antiretroviral therapy early after tuberculosis treatment.
    Ku NS; Oh JO; Shin SY; Kim SB; Kim HW; Jeong SJ; Han SH; Song YG; Kim JM; Choi JY
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):226-30. PubMed ID: 22881387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of tuberculosis treatment at combination antiretroviral therapy initiation on subsequent mortality: a systematic review and meta-analysis.
    Soeters HM; Poole C; Patel MR; Van Rie A
    PLoS One; 2013; 8(10):e78073. PubMed ID: 24143260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy.
    Karo B; Krause G; Castell S; Kollan C; Hamouda O; Haas W;
    BMC Infect Dis; 2017 Jul; 17(1):517. PubMed ID: 28743248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.
    Hung CC; Chen MY; Hsiao CF; Hsieh SM; Sheng WH; Chang SC
    AIDS; 2003 Dec; 17(18):2615-22. PubMed ID: 14685055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.
    Fairlie L; Karalius B; Patel K; van Dyke RB; Hazra R; Hernán MA; Siberry GK; Seage GR; Agwu A; Wiznia A;
    AIDS; 2015 Oct; 29(16):2109-19. PubMed ID: 26182197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era.
    Roul H; Mary-Krause M; Ghosn J; Delaugerre C; Pialoux G; Cuzin L; Launay O; Lacombe JM; Menard A; De Truchis P; Delfraissy JF; Weiss L; Costagliola D;
    AIDS; 2018 Nov; 32(17):2605-2614. PubMed ID: 30289817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
    Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
    PLoS One; 2015; 10(5):e0122587. PubMed ID: 25966339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy.
    Pantazis N; Papastamopoulos V; Paparizos V; Metallidis S; Adamis G; Antoniadou A; Psichogiou M; Chini M; Sambatakou H; Sipsas NV; Gogos C; Chrysos G; Panagopoulos P; Katsarou O; Gikas A; Touloumi G;
    AIDS; 2019 Aug; 33(10):1645-1655. PubMed ID: 31305332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration and task shifting for TB/HIV care and treatment in highly resource-scarce settings: one size may not fit all.
    Van Rie A; Patel MR; Nana M; Vanden Driessche K; Tabala M; Yotebieng M; Behets F
    J Acquir Immune Defic Syndr; 2014 Mar; 65(3):e110-7. PubMed ID: 24091692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients.
    Bouteloup V; Sabin C; Mocroft A; Gras L; Pantazis N; Le Moing V; d'Arminio Monforte A; Mary-Krause M; Roca B; Miro JM; Battegay M; Brockmeyer N; Berenguer J; Morlat P; Obel N; De Wit S; Fätkenheuer G; Zangerle R; Ghosn J; Pérez-Hoyos S; Campbell M; Prins M; Chêne G; Meyer L; Dorrucci M; Torti C; Thiébaut R;
    HIV Med; 2017 Jan; 18(1):33-44. PubMed ID: 27625009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.
    Dean GL; Edwards SG; Ives NJ; Matthews G; Fox EF; Navaratne L; Fisher M; Taylor GP; Miller R; Taylor CB; de Ruiter A; Pozniak AL
    AIDS; 2002 Jan; 16(1):75-83. PubMed ID: 11741165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
    Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
    AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short communication: effects of age on virologic suppression and CD4 cell response in HIV-positive patients initiating combination antiretroviral therapy.
    Szadkowski L; Tseng A; Walmsley SL; Salit I; Raboud JM
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1579-83. PubMed ID: 22734840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
    Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
    Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial.
    Laureillard D; Marcy O; Madec Y; Chea S; Chan S; Borand L; Fernandez M; Prak N; Kim C; Dim B; Nerrienet E; Sok T; Delfraissy JF; Goldfeld AE; Blanc FX;
    AIDS; 2013 Oct; 27(16):2577-86. PubMed ID: 24096631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?
    Jarrin I; Pantazis N; Dalmau J; Phillips AN; Olson A; Mussini C; Boufassa F; Costagliola D; Porter K; Blanco J; Del Amo J; Martinez-Picado J;
    AIDS; 2015 Nov; 29(17):2323-33. PubMed ID: 26544704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study.
    Franke MF; Robins JM; Mugabo J; Kaigamba F; Cain LE; Fleming JG; Murray MB
    PLoS Med; 2011 May; 8(5):e1001029. PubMed ID: 21559327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.